ResMed is a leader in CPAP machines and other medical devices that help millions breathe better.

On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating ...

Shares of medical device company ResMed (NYSE:RMD) fell 2.6% in the afternoon session after its Chairman and CEO, Michael J. Farrell, sold shares worth $1.25 million.

SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for ...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food ...

San Diego, California-based ResMed has received FDA 510(k) clearance for its small, portable continuous positive airway pressure (CPAP) device, the AirMini. The announcement was made during the JP ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, ...

We raise narrow-moat ResMed’s fair value estimate to USD 104 from USD 101 or AUD 14.90 from AUD 14.40 for the Australian listing. The increase is a function of tempering our medium-term sales ...

ResMed, Inc. RMD recently introduced its AirCurve 11 series devices. These are the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure and expiratory ...

If you are wondering whether ResMed's current share price still reflects good value or if most of the upside is already priced in, you are in the right place. ResMed shares last closed at US$230.84, ...

Coronavirus continues to suppress sleep apnea diagnosis rates and hence Resmed’s sleep device sales in third-quarter fiscal 2021, but still broadly track our full-year expectations for a ...